Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

We are pleased to announce The Max Foundation CEO and co-founder, Pat Garcia-Gonzalez, has been nominated as one of three finalists for the Outstanding Contribution to Cancer Control Award, by UICC. We are honored to see The Max Foundation’s efforts recognized by the UICC.

Pat Garcia-Gonzalez shared her gratitude, saying, “This nomination means the world to me and to all whose voices we represent. At The Max Foundation we believe that all people should be able to access the treatment they need, geography should not be destiny, and everyone should be able to strive for health with dignity and hope.

In the past 20 years we have demonstrated that it is possible to safely treat many cancers in low- and middle-income countries. Now we can prevent unnecessary suffering and premature death and because we can, we must.”

Pat is nominated in the civil society category, alongside Paul Farmer, Co-Founder and Chief Strategist, Partners in Health, and Maira Caleffi, breast surgeon and founder of FEMAMA. UICC has also nominated President Joe Biden, Minister Greg Hunt, and President Paul Kagame in the policy-makers category.

The panel of judges for UICC’s Outstanding Contribution to Cancer Control Awards includes: the members of the Board of the Union for International Cancer Control (UICC); the Editors in Chief of the three following scientific journals: Lancet Oncology, International Journal of CancerJournal of Global Oncology; and the CEO of the American Society for Clinical Pathology.

The Awards Ceremony will take place October 26th at the 2021 World Cancer Leaders’ Summit in Boston.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Inaugural ERSAP Prize Awarded to Pat Garcia-Gonzalez

    Estoril, Portugal– In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize. The International CML Foundation awarded our….

  • The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    The Max Foundation Announces CancerPath to Care to Treat Up to 36,000 People Living with Leukemia, Breast and Certain Rare Cancers in Over 70 Low- and Middle-income Countries by 2025

    New initiative expands existing collaboration with Novartis focused on chronic myeloid leukemia and other rare cancers, to support patient access to care for breast cancer, the leading cause of death in women globally

  • First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….